“ExplorerPlus will enable users to see more of their microbiome, provide comprehensive information on probiotic bacteria and functions of those bacteria." Dr. Jessica Richman, PhD, co-founder and CEO of uBiome
SAN FRANCISCO (PRWEB) May 08, 2018
uBiome, the leader in microbial genomics, today revealed new features for its groundbreaking ExplorerPlus product. Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, spoke about the product’s unique capabilities during a panel discussion at the first annual HLTH Conference in Las Vegas.
Launched in January 2018, ExplorerPlus, is the next generation of the company’s popular Explorer™ health and wellness product. The test uses uBiome’s precision sequencing™ platform, a patented combination of full metagenomic and marker-based sequencing that enables users to see more of their microbiome -- including viruses and fungi, as well as archaea (single-celled microorganisms) and bacteria. In addition, ExplorerPlus will now offer consumers insights on the key metabolites and vitamins that are being synthesized by the bacteria in their microbiome, extensive information on probiotic bacteria, and downloadable raw data for every organism detected in their sample.
“ExplorerPlus will enable users to see more of their microbiome, provide comprehensive information on probiotic bacteria and functions of those bacteria,” said Dr. Jessica Richman, PhD, co-founder and CEO of uBiome. “This technology is the next step in the evolution of uBiome’s products to more fully understand the human microbiome in the context of health and wellness.”
Explorer has been used by hundreds of thousands of consumers in almost every country in the world, as well as by more than 200 prestigious research institutions around the world. Citizen scientists and wellness enthusiasts have enjoyed learning more about their microbiomes in the context of health and wellness. ExplorerPlus will allow these users to learn more about their samples and to participate in expanded research opportunities. To learn more about ExplorerPlus, please visit the uBiome website.
uBiome’s technology platform is based on the largest dataset of human microbiomes in the world (over 250,000 samples), covered by six issued patents (and over 100 pending applications), and used in over 20 peer-reviewed publications and presentations. This platform has been used by over 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, University of California, San Francisco, University College London, and University of Sydney.
The company’s Scientific Advisory Board includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), and other leading scientists. Their Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Robynne Chutkan (Georgetown University Hospital), and Michael Docktor (Boston Children’s Hospital).
Founded in 2012, uBiome is the world’s leading microbial genomics company with a mission to transform the science of the microbiome into reliable, accurate products and services that improve people’s lives. uBiome is funded by Y Combinator, Andreessen Horowitz, and 8VC, as well as other leading investors. The company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018.